Saturday 17 October 2026
Export HROW’s income statement to Excel — free account
Harrow, Inc.
HROW Healthcare Drug Manufacturers Specialty & Generic
Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
27.28
1.47
−5.11%
Follow HROW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.16 | 6.61 | 4.89 | 5.76 | |
P/FCF ratio |
0.00 | 42.12 | 0.00 | 0.00 | |
P/Operating CF |
107.89 | 214.16 | (145.99) | (162.61) | |
P/B ratio |
38.35 | 34.58 | 46.30 | 106.86 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.85 | 7.25 | 5.64 | 6.53 | |
EV/EBITDA |
37.55 | 36.42 | 34.86 | 84.00 | |
EV/Operating CF |
111.02 | 45.04 | 99.59 | 287.69 | |
EV/FCF |
(95.18) | 46.20 | (389.33) | (137.49) | |
Quick Ratio |
2.32 | 1.91 | 2.14 | 1.98 | |
Current Ratio |
2.72 | 2.20 | 2.48 | 2.24 | |
Net Debt/EBITDA |
8.12 | 8.14 | (12.45) | (47.14) | |
Debt/Assets |
66.89% | 60.87% | 69.62% | 70.15% | |
Debt/Equity |
5.21 | 4.67 | 10.30 | 19.70 | |
Asset Turnover |
0.70 | 0.69 | 0.69 | 0.72 | |
Operating CF/Net income |
16.26 | 1.27 | 0.33 | 0.56 | |
Capex/Depreciation |
(0.04) | (0.07) | (2.92) | (0.08) | |
Interest Coverage |
2.44 | 3.01 | (4.02) | (1.76) | |
Research and Development Expense of Revenue |
4.64% | 13.16% | 13.34% | 11.42% | |
Selling, General and Administrative Expense of Revenue |
50.05% | 48.61% | 97.80% | 75.43% | |
Intangible Assets out of Total Assets |
0.48 | 0.44 | 0.43 | 0.42 | |
Share Based Compensation of Revenue |
4.57% | 4.27% | 8.68% | 5.36% | |
Graham Net Nets |
(0.08) | (0.08) | (0.13) | (0.11) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.29%) | (0.31%) | (1.11%) | (2.33%) | |
Free Cash Flow Yield |
(1.15%) | 2.37% | (0.30%) | (0.82%) | |
Revenue per Share |
1.93 | 2.42 | 1.19 | 1.89 | |
Operating CF per Share |
0.45 | 0.23 | (0.24) | (0.26) | |
Capex per Share |
(0.01) | (0.01) | (0.49) | (0.01) | |
Free Cash Flow per Share |
0.44 | 0.22 | (0.73) | (0.28) | |
Cash per Share |
2.00 | 1.98 | 2.54 | 2.25 | |
Shareholders Equity per Share |
1.26 | 1.42 | 0.76 | 0.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.26 | 1.42 | 0.76 | 0.40 | |
Free Cash Flow |
16.36 | 8.04 | (27.19) | (10.29) | |
Working Capital |
112.20 | 115.45 | 134.95 | 127.14 | |
Capital Expenditures |
(0.22) | (0.37) | (18.20) | (0.53) | |
Net Current Asset Value |
(138.81) | (135.64) | (164.81) | (172.66) | |
EV/EBIT |
70.52 | 64.74 | 76.99 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.41 | 0.01 | |
Price to Operating Income |
64.32 | 59.03 | 66.75 | 0.00 | |
| Other line items | |||||
Average Receivables |
65.67 | 113.63 | 89.16 | 98.69 | |
Average Payables |
22.72 | 41.68 | 34.59 | 29.74 | |
Average Inventory |
11.50 | 12.11 | 13.61 | 14.23 | |
Average Assets |
357.31 | 394.23 | 391.85 | 380.92 | |
Average Common Equity |
52.14 | 60.69 | 42.22 | 32.07 |
Columns are period end dates